Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.

Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.

IL-15 helps hair grow longer and stronger by extending the growth phase and reducing cell death.

More precise, personalized therapies are needed for autoimmune diseases.

SARS-CoV-2 proteins help the virus avoid the immune system, delaying response and increasing inflammation.

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

Similar treatments might work for different types of scarring hair loss.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Upadacitinib may cause hair loss.

RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Low dose methotrexate does not increase hair fall and may reduce it.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Tofacitinib is effective and safe for treating severe alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A new microneedle patch helps repair spinal cord injuries by reducing scarring and promoting nerve growth.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

The summit aimed to speed up finding treatments for alopecia areata.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.